Amy Feldman

1 week ago | forbes.co | Amy Feldman

El cofundador y director ejecutivo de Colossal Biosciences, Ben Lamm, tiene una fortuna de 3.700 millones de dólares tras la reciente recaudación de fondos de la compañía, que alcanzó una impresionante valoración de 10.200 millones de dólares. Sin embargo, aún no se le ha pagado por revivir animales extintos o salvar a los que están en peligro de extinción. El empresario industrial Ben Lamm y el genetista de Harvard George Church fundaron Colossal Biosciences en 2021 para rescatar al mamut lanudo.

1 week ago | forbes.com | Amy Feldman

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center. After all, why spend millions trying to develop novel medications in the U.S. when Chinese firms have probably already done it for you? In the summer of 2023, Dr. Amir Zamani, a 42-year-old Johns Hopkins–trained physician who is a partner on Bain Capital’s life sciences team in Boston, was obsessed with obesity drugs.

1 week ago | forbes.com | Amy Feldman

When Dr. David Reese, Amgen’s first chief technology officer, set about hiring a head of artificial intelligence last year, he looked at people who’d worked in consumer products, finance and other areas. He ended up finding one in shoes. Last August, he brought on Sean Bruich, who’d spent the past 11 years of his career working at Nike, as senior vice president for AI and data, a move that might seem almost laughably incongruous.

2 weeks ago | forbes.com | Amy Feldman

In this week’s edition of InnovationRx, we look at the impact of tariffs on healthcare costs, pioneers of treating MS, AI for clinical decision-making, and more. To get it in your inbox, subscribe here. Last week, Trump made good on a core campaign promise to enact sweeping tariffs, slapping a baseline of 10% tax on imports from every country, with many others singled out for harsher rates, with China now set at 108%.

2 weeks ago | jamanetwork.com | Amy Feldman

Postvaccination Immunogenicity Among Pediatric Solid Organ Transplant Recipients A global resurgence of measles and mumps has challenged the historical recommendation to avoid live attenuated viral vaccines (LVVs)—including the measles, mumps, rubella (MMR) and varicella zoster virus (VZV) vaccines—after solid organ transplant (SOT).1-3 A recent multicenter cohort study of 281 pediatric patients who received an LVV post-SOT demonstrated short-term safety and immunogenicity.4 We assessed...